Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | EVP HR & CHRO | February 25, 2022 | February 28, 2022 |
| Fortrea Holdings Inc.FTRE · Entity 4623 | Former Director | March 30, 2024 | April 01, 2024 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Chief People Officer | March 01, 2024 | March 05, 2024 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Chief HR Officer | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date February 25, 2022 · Filed February 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,872 |
Ending reported balance
After 2022-02-25 transaction · row 24
24 source rows · reconciled sequenceRow 1 · 2022-02-25 · Exercise / conversion · Acquired 3,613 · Balance 9,485 Row 2 · 2022-02-25 · Disposition to issuer · Disposed 1,463 · Balance 8,022 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 3 · 2022-02-25 · Sale · Disposed 2,150 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 4 · 2022-02-25 · Exercise / conversion · Acquired 7,076 · Balance 12,948 Row 5 · 2022-02-25 · Disposition to issuer · Disposed 3,162 · Balance 9,786 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 6 · 2022-02-25 · Sale · Disposed 3,914 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 7 · 2022-02-25 · Exercise / conversion · Acquired 9,377 · Balance 15,249 Row 8 · 2022-02-25 · Disposition to issuer · Disposed 4,935 · Balance 10,314 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 9 · 2022-02-25 · Sale · Disposed 4,442 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 10 · 2022-02-25 · Exercise / conversion · Acquired 10,245 · Balance 16,117 Row 11 · 2022-02-25 · Disposition to issuer · Disposed 8,209 · Balance 7,908 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 12 · 2022-02-25 · Sale · Disposed 2,036 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 13 · 2022-02-25 · Exercise / conversion · Acquired 6,789 · Balance 12,661 Row 14 · 2022-02-25 · Disposition to issuer · Disposed 6,045 · Balance 6,616 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 15 · 2022-02-25 · Sale · Disposed 744 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 16 · 2022-02-25 · Exercise / conversion · Acquired 4,630 · Balance 10,502 Row 17 · 2022-02-25 · Disposition to issuer · Disposed 4,346 · Balance 6,156 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 18 · 2022-02-25 · Sale · Disposed 284 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 19 · 2022-02-25 · Exercise / conversion · Acquired 1,244 · Balance 7,116 Row 20 · 2022-02-25 · Disposition to issuer · Disposed 1,041 · Balance 6,075 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 21 · 2022-02-25 · Sale · Disposed 203 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 22 · 2022-02-25 · Exercise / conversion · Acquired 3,684 · Balance 9,556 Row 23 · 2022-02-25 · Disposition to issuer · Disposed 3,083 · Balance 6,473 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Row 24 · 2022-02-25 · Sale · Disposed 601 · Balance 5,872 F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $110.04 · Expires 2024-12-10 | Direct | 0 |
Reported balance
After 2022-02-25 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2022-02-25 · Exercise / conversion · Disposed 3,613 · Balance 0 F2: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $121.49 · Expires 2025-12-09 | Direct | 0 |
Reported balance
After 2022-02-25 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2022-02-25 · Exercise / conversion · Disposed 7,076 · Balance 0 F2: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $143.07 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2022-02-25 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2022-02-25 · Exercise / conversion · Disposed 9,377 · Balance 0 F2: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $217.84 · Expires 2028-01-02 | Direct | 0 |
Reported balance
After 2022-02-25 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2022-02-25 · Exercise / conversion · Disposed 10,245 · Balance 0 F3: The stock appreciation rights vest in four annual installments beginning January 2, 2019. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $242.10 · Expires 2028-11-26 | Direct | 2,265 |
Reported balance
After 2022-02-25 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2022-02-25 · Exercise / conversion · Disposed 6,789 · Balance 2,265 F4: The stock appreciation rights vest in four annual installments beginning November 26, 2019. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $255.22 · Expires 2029-11-26 | Direct | 4,630 |
Reported balance
After 2022-02-25 transaction · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · 2022-02-25 · Exercise / conversion · Disposed 4,630 · Balance 4,630 F5: The stock appreciation rights vest in four annual installments beginning November 26, 2020. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $227.47 · Expires 2030-11-26 | Direct | 2,490 |
Reported balance
After 2022-02-25 transaction · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · 2022-02-25 · Exercise / conversion · Disposed 1,244 · Balance 2,490 F6: The stock appreciation rights vest in four annual installments beginning November 26, 2021. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $227.47 · Expires 2030-11-26 | Direct | 11,052 |
Reported balance
After 2022-02-25 transaction · row 32
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 32 · 2022-02-25 · Exercise / conversion · Disposed 3,684 · Balance 11,052 F6: The stock appreciation rights vest in four annual installments beginning November 26, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request.
F2: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action.
F3: The stock appreciation rights vest in four annual installments beginning January 2, 2019.
F4: The stock appreciation rights vest in four annual installments beginning November 26, 2019.
F5: The stock appreciation rights vest in four annual installments beginning November 26, 2020.
F6: The stock appreciation rights vest in four annual installments beginning November 26, 2021.
Fortrea Holdings Inc.
Report date March 30, 2024 · Filed April 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,354 |
Reported balance
After 2024-03-30 transaction · row 1
1 source rowRow 1 · 2024-03-30 · Exercise / conversion · Acquired 6,354 · Balance 6,354 F1: The Management Development and Compensation Committee of Board of Directors approved, immediately upon the Reporting Person's resignation from the Board of Directors, accelerated vesting of 6,354 Restricted Stock Units that were otherwise scheduled to vest on July 18, 2024. These Restricted Stock Units converted into common stock on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-30 · Exercise / conversion · Disposed 6,354 · Balance 0 F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. This transaction represents the settlement of RSUs in shares of Common Stock. F1: The Management Development and Compensation Committee of Board of Directors approved, immediately upon the Reporting Person's resignation from the Board of Directors, accelerated vesting of 6,354 Restricted Stock Units that were otherwise scheduled to vest on July 18, 2024. These Restricted Stock Units converted into common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: The Management Development and Compensation Committee of Board of Directors approved, immediately upon the Reporting Person's resignation from the Board of Directors, accelerated vesting of 6,354 Restricted Stock Units that were otherwise scheduled to vest on July 18, 2024. These Restricted Stock Units converted into common stock on a one-for-one basis.
F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. This transaction represents the settlement of RSUs in shares of Common Stock.
GE HealthCare Technologies Inc.
Report date March 01, 2024 · Filed March 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 50,936 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Tax withholding · Disposed 7,472 · Balance 54,459 F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Row 2 · 2024-03-01 · Tax withholding · Disposed 3,523 · Balance 50,936 F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 7,954 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 7,954 · Balance 7,954 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 23,283 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 23,283 · Balance 23,283 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Common StockSEC Table I · non-derivative | Direct | 13,774 |
Reported balance
Holding disclosure · report date 2026-05-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,774 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BARD C R INC /NJ/
Report date December 29, 2017 · Filed January 03, 2018
Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,454 |
Reported balance
After 2017-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-12-29 · Grant · Acquired 5,502 · Balance 13,454 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger. F2: Includes 5,502 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units. |
| Common StockSEC Table I · non-derivative | Direct | 12,996 |
Reported balance
After 2017-12-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-12-29 · Disposition to issuer · Disposed 458 · Balance 12,996 F3: Includes 458 Bard shares that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | Direct | 9,317 |
Reported balance
After 2017-12-29 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-12-29 · Disposition to issuer · Disposed 3,679 · Balance 9,317 F4: Includes 3,679 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units. |
| Common StockSEC Table I · non-derivative | Direct | 5,502 |
Reported balance
After 2017-12-29 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2017-12-29 · Disposition to issuer · Disposed 3,815 · Balance 5,502 F5: Includes 3,815 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was cancelled and converted into an equivalent adjusted BD MSPP Unit. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2017-12-29 · Disposition to issuer · Disposed 5,502 · Balance 0 F2: Includes 5,502 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.06 · Expires 2024-09-02 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-29 · Disposition to issuer · Disposed 2,016 · Balance 0 F6: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $186.43 · Expires 2025-12-09 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-12-29 · Disposition to issuer · Disposed 4,611 · Balance 0 F6: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.87 · Expires 2024-12-10 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-12-29 · Disposition to issuer · Disposed 2,355 · Balance 0 F6: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $219.56 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-12-29 · Disposition to issuer · Disposed 6,111 · Balance 0 F6: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger.
F2: Includes 5,502 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
F3: Includes 458 Bard shares that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.
F4: Includes 3,679 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.
F5: Includes 3,815 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was cancelled and converted into an equivalent adjusted BD MSPP Unit.
F6: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 16:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 23,283 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000131 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,283 Underlying: Common Stock · 23,283 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 7,954 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000131 · form4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,954 Underlying: Common Stock · 7,954 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 11,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000084 · form4.xml · derivative · entry 6 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,350 Underlying: Common Stock · 11,350 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 5,143 | $110.95 | $570,615.85 |
DisclosureSEC source: 0000310158-26-000084 · form4.xml · nonDerivative · entry 4 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,774 Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 11,350 | $110.95 | $1,259,282.50 |
DisclosureSEC source: 0000310158-26-000084 · form4.xml · nonDerivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,085 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000084 · form4.xml · derivative · entry 5 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,172 Underlying: Common Stock · 2,085 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 715 | $110.03 | $78,671.45 |
DisclosureSEC source: 0000310158-26-000084 · form4.xml · nonDerivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,567 Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,085 | $110.03 | $229,412.55 |
DisclosureSEC source: 0000310158-26-000084 · form4.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 11,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013174 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 11,350 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 5,153 | $84.71 | $436,510.63 |
DisclosureSEC source: 0001127602-25-013174 · form4.xml · nonDerivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,197 Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 11,350 | $84.71 | $961,458.50 |
DisclosureSEC source: 0001127602-25-013174 · form4.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 28,479 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013031 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,479 Underlying: Common Stock · 28,479 shares Expires 2035-04-28 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 6,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013031 · form4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,257 Underlying: Common Stock · 6,257 shares Expires 2028-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 31,055 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013989 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,055 Underlying: Common Stock · 31,055 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 58,594 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013989 · form4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,594 Underlying: Common Stock · 58,594 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 34,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013989 · form4.xml · derivative · entry 1 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,050 Underlying: Common Stock · 34,050 shares Expires 2027-04-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| March 30, 2024 Filed Apr 1, 2024 10:33 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011474 · form4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. This transaction represents the settlement of RSUs in shares of Common Stock. F1 · derivative.exercise_date: The Management Development and Compensation Committee of Board of Directors approved, immediately upon the Reporting Person's resignation from the Board of Directors, accelerated vesting of 6,354 Restricted Stock Units that were otherwise scheduled to vest on July 18, 2024. These Restricted Stock Units converted into common stock on a one-for-one basis. F1 · derivative.expiration_date: The Management Development and Compensation Committee of Board of Directors approved, immediately upon the Reporting Person's resignation from the Board of Directors, accelerated vesting of 6,354 Restricted Stock Units that were otherwise scheduled to vest on July 18, 2024. These Restricted Stock Units converted into common stock on a one-for-one basis. Read SEC document |
| March 30, 2024 Filed Apr 1, 2024 10:33 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011474 · form4.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Management Development and Compensation Committee of Board of Directors approved, immediately upon the Reporting Person's resignation from the Board of Directors, accelerated vesting of 6,354 Restricted Stock Units that were otherwise scheduled to vest on July 18, 2024. These Restricted Stock Units converted into common stock on a one-for-one basis. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:53 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 3,523 | $91.28 | $321,579.44 |
DisclosureSEC source: 0001628280-24-009076 · wk-form4_1709679168.xml · nonDerivative · entry 2 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,936 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:53 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 7,472 | $91.28 | $682,044.16 |
DisclosureSEC source: 0001628280-24-009076 · wk-form4_1709679168.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,459 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 21:13 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-021042 · form4.xml · derivative · entry 1 Larson Betty D · CIK 0001617903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:52 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 23,156 | Not disclosed Strike: $75.30 | Not disclosed |
DisclosureSEC source: 0001628280-23-006428 · wf-form4_167789112527523.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,156 Underlying: Common Stock, par value $0.01 per share · 23,156 shares Expires 2033-03-01 F3 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2024, 33% will become exercisable on September 1, 2025, and 34% will become exercisable on September 1, 2026. F3 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2024, 33% will become exercisable on September 1, 2025, and 34% will become exercisable on September 1, 2026. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:52 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 8,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-006428 · wf-form4_167789112527523.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,931 F1 · shares: Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 33% will vest on September 1, 2024, 33% will vest on September 1, 2025, and 34% will vest on September 1, 2026. F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:03 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 39,193 | Not disclosed Strike: $70.01 | Not disclosed |
DisclosureSEC source: 0001628280-23-002269 · wf-form4_167546537520559.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,193 Underlying: Common Stock, par value $0.01 per share · 39,193 shares Expires 2033-02-01 F4 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 50% will become exercisable on February 1, 2025 and 50% will become exercisable on February 1, 2026. F4 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 50% will become exercisable on February 1, 2025 and 50% will become exercisable on February 1, 2026. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:03 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 4,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-002269 · wf-form4_167546537520559.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,631 F1 · shares: Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 50% will vest on February 1, 2025 and 50% will vest on February 1, 2026. F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. F3 · balance_after: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes 4,463 newly awarded restricted stock units and 49,168 previously reported restricted stock units. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 01:52 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantRestricted Stock Units · Derivative | 32,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-001120 · doc4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,779 Underlying: Common stock, par value $0.01 per share · 32,779 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. F2 · price: Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025. F2 · derivative.exercise_date: Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025. F2 · derivative.expiration_date: Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 01:52 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantRestricted Stock Units · Derivative | 16,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-001120 · doc4.xml · derivative · entry 1 Larson Betty D · CIK 0001617903 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,389 Underlying: Common stock, par value $0.01 per share · 16,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. F2 · price: Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025. F2 · derivative.exercise_date: Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025. F2 · derivative.expiration_date: Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 3,684 | $0.00 Strike: $227.47 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 32 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,052 Underlying: Common Stock · 3,684 shares Expires 2030-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2021. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 1,244 | $0.00 Strike: $227.47 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 31 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 1,244 shares Expires 2030-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2021. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 4,630 | $0.00 Strike: $255.22 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 30 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,630 Underlying: Common Stock · 4,630 shares Expires 2029-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2020. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 6,789 | $0.00 Strike: $242.10 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 29 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,265 Underlying: Common Stock · 6,789 shares Expires 2028-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2019. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 10,245 | $0.00 Strike: $217.84 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 28 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,245 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning January 2, 2019. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 9,377 | $0.00 Strike: $143.07 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 27 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,377 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 7,076 | $0.00 Strike: $121.49 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 26 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,076 shares Expires 2025-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 3,613 | $0.00 Strike: $110.04 | $0.00 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · derivative · entry 25 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,613 shares Expires 2024-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning on the one year anniversary of the grant date. Unvested stock appreciation rights on December 29, 2017 vested in full due to corporate action. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 601 | $271.90 | $163,411.90 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 24 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,872 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 3,083 | $271.90 | $838,267.70 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 23 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,473 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 3,684 | $227.47 | $837,999.48 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 22 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 203 | $271.90 | $55,195.70 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 21 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,872 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 1,041 | $271.90 | $283,047.90 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 20 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,075 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 1,244 | $227.47 | $282,972.68 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 19 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 284 | $271.90 | $77,219.60 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 18 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,872 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 4,346 | $271.90 | $1,181,677.40 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 17 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,156 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 4,630 | $255.22 | $1,181,668.60 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 16 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 744 | $271.90 | $202,293.60 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 15 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,872 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 6,045 | $271.90 | $1,643,635.50 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 14 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,616 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 6,789 | $242.10 | $1,643,616.90 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 13 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 2,036 | $271.90 | $553,588.40 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 12 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,872 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 8,209 | $271.90 | $2,232,027.10 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 11 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,908 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $271.27 through $272.47. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 20:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 10,245 | $217.84 | $2,231,770.80 |
DisclosureSEC source: 0001062993-22-005887 · form4.xml · nonDerivative · entry 10 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.